EGFR (L792F)
Sign in to save this workspaceEGFR · Variant type: point · HGVS: p.L792F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Osimertinib | 100.0% | 0.0% | 97.24 |
| 2 | Canertinib | 100.0% | 0.0% | 96.49 |
| 3 | Vandetanib | 99.9% | 0.1% | 95.74 |
| 4 | Ibrutinib | 99.6% | 0.4% | 94.74 |
| 5 | Erlotinib | 99.6% | 0.4% | 99.75 |
| 6 | Mobocertinib | 99.5% | 0.5% | 97.22 |
| 7 | Neratinib | 99.5% | 0.5% | 93.18 |
| 8 | Lazertinib | 99.4% | 0.6% | 97.47 |
| 9 | Lapatinib | 99.3% | 0.7% | 99.25 |
| 10 | Fostamatinib | 98.5% | 1.5% | 96.74 |
| 11 | Dacomitinib | 98.4% | 1.6% | 97.99 |
| 12 | Defactinib | 95.0% | 5.0% | 92.68 |
| 13 | Zanubrutinib | 94.0% | 6.0% | 98.24 |
| 14 | Pacritinib | 93.1% | 6.9% | 88.64 |
| 15 | Brigatinib | 80.3% | 19.7% | 82.96 |
| 16 | Pralsetinib | 77.3% | 22.7% | 93.43 |
| 17 | Avapritinib | 69.2% | 30.8% | 97.73 |
| 18 | Gilteritinib | 68.2% | 31.8% | 88.97 |
| 19 | Deucravacitinib | 52.3% | 47.7% | 98.99 |
| 20 | Fedratinib | 49.0% | 51.0% | 96.21 |
| 21 | Pirtobrutinib | 44.6% | 55.4% | 99.49 |
| 22 | Pazopanib | 43.2% | 56.8% | 97.49 |
| 23 | Capmatinib | 43.1% | 56.9% | 99.75 |
| 24 | Alpelisib | 32.0% | 68.0% | 97.22 |
| 25 | Vemurafenib | 27.0% | 73.0% | 96.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Osimertinib | 100.0% | 99.1% | +0.9% |
| Canertinib | 100.0% | 98.4% | +1.6% |
| Vandetanib | 99.9% | 99.3% | +0.6% |
| Ibrutinib | 99.6% | 99.3% | +0.3% |
| Erlotinib | 99.6% | 99.4% | +0.2% |
| Mobocertinib | 99.5% | 100.0% | -0.5% |
| Neratinib | 99.5% | 100.0% | -0.5% |
| Lazertinib | 99.4% | 100.0% | -0.6% |
| Lapatinib | 99.3% | 99.2% | +0.1% |
| Fostamatinib | 98.5% | 97.8% | +0.7% |
| Dacomitinib | 98.4% | 99.8% | -1.4% |
| Defactinib | 95.0% | 94.6% | +0.5% |
| Zanubrutinib | 94.0% | 88.2% | +5.8% |
| Pacritinib | 93.1% | — | — |
| Brigatinib | 80.3% | 98.5% | -18.1% |
| Pralsetinib | 77.3% | 99.1% | -21.9% |
| Avapritinib | 69.2% | — | — |
| Gilteritinib | 68.2% | 91.0% | -22.8% |
| Deucravacitinib | 52.3% | — | — |
| Fedratinib | 49.0% | — | — |
| Pirtobrutinib | 44.6% | — | — |
| Pazopanib | 43.2% | — | — |
| Capmatinib | 43.1% | — | — |
| Alpelisib | 32.0% | — | — |
| Vemurafenib | 27.0% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.5ms